Table 3. Correlation between serum ApoA-1 levels and clinicopathologic characteristics.

Clinical characteristics		Training cohort			Validation cohort
		ApoA-1 ≤1.04g/L (N=82)	ApoA-1 >1.04g/L (N=142)	P	ApoA-1 ≤1.04g/L (N=55)	ApoA-1 >1.04g/L (N=164)	P
Age	≤50	32	53	0.886	20	67	0.634
	>50	50	89		35	97
Sex	Female	9	24	0.248	5	35	0.045a
	Male	73	118		50	129
AFP, ng/mL	≤400	56	101	0.653	28	126	0.001
	>400	26	41		27	38
ALT, U/L	≤75	78	133	0.773a	50	151	0.780a
	>75	4	9		5	13
γ-GT, U/L	≤54	55	76	0.050	35	92	0.348
	>54	27	66		20	72
HBsAg	Negative	10	18	1.000	11	19	0.120
	Positive	72	124		44	145
Liver cirrhosis	No	20	31	0.741	16	41	0.595
	Yes	62	111		39	123
No. of tumor	Single	59	121	0.023	43	139	0.299
	Multiple	23	21		12	25
Tumor size, cm	≤5	48	93	0.317	27	104	0.080
	>5	34	48		28	60
Tumor encapsulation	Complete	47	93	0.253	34	111	0.510
	None	35	49		21	53
Satellite lesion	No	70	129	0.271	49	150	0.594
	Yes	12	13		6	14
Vascular invasion	No	46	91	0.257	27	98	0.208
	Yes	36	51		28	66
Tumor differentation	I-II	47	95	0.195	30	111	0.103
	III-IV	35	47		25	53
Child-Pugh score	A	76	134	0.775	50	149	1.000a
	B	6	8		5	15
BCLC stage	0+A	52	114	0.007	36	127	0.107
	B+C	30	28		19	37

Abbreviations: AFP, α-fetoprotein; ALT, alanine aminotransferase; γ-GT, γ-Glutamyltransferase; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; ApoA-1, Apolipoprotein A1.

^aFisher exact test.